Organic Active Ingredients TRIZ Cases

Combined TGF-β1/TGF-β2 and CTGF therapy promotes collagen repair in injured connective tissue while helping reduce swelling and pain.

Room-stable fibrinogen and thrombin solutions cut thawing steps, extend usability, and reduce waste of scarce fibrinogen.

Blood mRNA is reverse transcribed and optically detected to distinguish bacterial, viral, and non-infectious ARI causes for better treatment.

Sequential cord blood Treg isolation and IL-2/CD3-CD28 expansion create a ready cell therapy to suppress auto-reactive T cells and inflammation.

Peripherally restricted CB1 antagonists block receptors in metabolic tissues while avoiding blood-brain barrier penetration and CNS side effects.

Oral cG-2-AllylP restores IGF-1, normalizes AKT and ERK, and rescues dendritic defects linked to Pitt Hopkins syndrome.

Targeting PKR or eIF2α phosphorylation can suppress toxic RAN protein translation while helping preserve normal translation in repeat-expansion diseases.

These aromatic compounds improve glycemic control and lower plasma insulin while helping prevent hepatic fibrosis and steatosis.

Lipid and amino acid surface treatment controls silicon nanoparticle hydrolysis, stabilizing orthosilicic acid and active-agent release.

A sublingual eliglustat composition bypasses first-pass metabolism to raise bioavailability, reduce dosing, and speed therapeutic effect.

Acylated glucagon analogues use fatty-chain peptide tuning to balance GLP-1 and glucagon receptor activity for weight loss and glucose control.

A 0.45 μm pre-filter and 0.2 μm sterilizing filter keep timolol gel sterile while controlling viscosity and avoiding heat damage.

SBEβCD inclusion complexing with bicarbonate raises meloxicam solubility and absorption, supporting faster, sustained relief for migraine pain.

A softgel combining curcumin, carotenoids, omega-3s, vitamin E, and zinc improves macular pigment support, glare recovery, and visual speed.

Oral masitinib targets sickle cell crises and acute chest syndrome when current therapies are inadequate or unsuitable for some patients.

A thin ocular film uses a biocompatible liquid depot to resist tears and release drug steadily for days without vision impairment.

Stealth polymer-coated protein nanoparticles enable inhaled siRNA and antibody delivery with better lung targeting, uptake, and nuclease protection.

Local nanocarrier delivery of immunosuppressants with therapeutic macromolecules reduces Type I and IV hypersensitivity while limiting systemic side effects.

Crystalline acid salts of an FGFR inhibitor improve handling, storage stability, purification, dissolution, and bioavailability for cancer formulations.

Critically spaced tiopronin pulses lower peak blood levels while sustaining urinary exposure to control nighttime cystine and reduce side effects.

Tricyclic amide EZH2 inhibitors improve selectivity and pharmacodynamic effects through targeted scaffold and substitution design.

Polymer-based amorphous dispersions stabilize oily ITI-007, prevent crystallization, and maintain over 90% stability under heat and humidity.

Analyte signatures from blood, saliva, urine, or stool help match obesity phenotypes to drug treatments with more consistent weight loss and fewer side effects.

Liver-targeted polymethine dye nanocarriers deliver PKC inhibitors for septic cholestasis while limiting systemic immune suppression and dose.

Spray-dried amorphous adrenaline powder with maltodextrin improves stability, shelf-life, and rapid intranasal absorption.

Combining a RIG-I agonist with PD-1 or PD-L1 blockade boosts interferon signaling, delays tumor growth, and limits inflammatory side effects.

Specific bacterial strains boost vitamin D absorption and serum levels faster while avoiding the cholesterol-related limits of conventional therapy.

Non-covalent albumin binding improves ophthalmic drug solubility and reduces burning and stinging while maintaining treatment efficacy.

Controlled sulfation of gluco-galacto-oligosaccharides inhibits factor Xa and thrombin generation while limiting bleeding risk.

A vaccinia-inflamed rabbit skin extract is paired with cytotoxic drugs to reduce side effects while preserving anti-tumor activity.

Oral riluzole prodrugs resist rapid hepatic metabolism and release riluzole in plasma for more predictable exposure and fewer liver-related effects.

CoQ10 co-administration helps protect healthy cells during chemotherapy, reducing side effects while supporting tumor reduction and survival time.

Trisulfide compounds strengthen HGF-c-Met binding to boost HGF-driven cell proliferation and physiological activity for regenerative therapy.

A guanidine derivative composition promotes hair growth and follicle regeneration while avoiding the side effects of surgery and minoxidil.

Combining 5% minoxidil with 0.07-0.095% finasteride in foam or liniment improves alopecia response speed while limiting irritation and side effects.

Phthalazinone-based modulators vary core substituents and ring structures to kill cancer cells and inhibit proliferation across cancer types.

Antibody capture plus peptide mass spectrometry enables sensitive UBE3A quantification for Angelman syndrome diagnosis and therapy monitoring.

Serological screening and elevated CRP or ESR guide secukinumab dosing to improve response and sustained joint symptom control.

Machine learning-guided in silico screening narrows millions of compounds to validated antibacterial candidates, cutting discovery time and cost.

Structured CBC derivatives expand treatment across cancer, neurological disorders, and pain while enabling more controlled dosing.

Amorphous dasatinib dispersions use polymer matrices to maintain oral exposure despite elevated gastric pH or acid-reducing co-therapy.

Pyridine derivatives use targeted substitutions to block CCR2/CCR5 while avoiding CYP450 inhibition, improving inflammatory disease drug safety.

3-benzoyl-pyrrolopyridine derivatives selectively inhibit MKK4 over MKK7 and JNK1 to promote liver regeneration and reduce hepatocyte death.

Non-nucleoside bicyclic pyridone compounds inhibit herpesvirus DNA polymerases to address resistance and reduce side effects.

Targeted dsRNA silences ANGPTL3 mRNA through RNA interference, lowering serum lipids, triglycerides, and cholesterol.

Deuterium-enriched gaboxadol extends therapeutic benefit in developmental disorders while lowering peak plasma exposure and reducing dosing frequency.

Using the hydrogen sulphate salt in a carrier matrix improves solubility, dissolution, and storage stability for reliable bioavailability.

Effector-activated allosteric antibodies restore antigen binding at the target site, reducing systemic side effects and infection risk.

Water extraction of sweet basil polyphenols and triterpenes creates a low-cost topical or oral composition that inhibits HSV and speeds ulcer healing.

Monohydrate crystal forms MH1 and MH2 improve PDE9 inhibitor solubility, oral bioavailability, and physical stability for oral dosing.